Monday, April 20, 2015 8:05:13 PM
I don't know. I think given the size of the global neutriceutical market and the apparent substantial efficacy improvements offered by Plandai's GT, there's a third road. They mentioned on the video that they've already deployed sales people who, if businesses are paying attention, should be ar least getting in the door for some serious conversations. Once they present the data to key buyers, I think we have the potential to see a number of contracts coming in. Since it looks like production is underway, couldn't we see some deliveries starting at the end of summer? If so we should see revenues this next quarter.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM